NCT04118140

Brief Summary

Using a robust research method following the MRC Framework, the proposed study will develop and test an evidence-based complementary health intervention to help breast cancer patients manage the fatigue-sleep disturbance-depression symptom cluster.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for not_applicable cancer

Timeline
Completed

Started Mar 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 27, 2019

Completed
11 days until next milestone

First Posted

Study publicly available on registry

October 8, 2019

Completed
1.4 years until next milestone

Study Start

First participant enrolled

March 15, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 17, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 20, 2022

Completed
Last Updated

July 21, 2022

Status Verified

July 1, 2022

Enrollment Period

1.2 years

First QC Date

September 27, 2019

Last Update Submit

July 19, 2022

Conditions

Keywords

Canceracupressurefatiguedepressioninsomniasymptom cluster

Outcome Measures

Primary Outcomes (12)

  • FEASIBILITY: Eligibility rate

    Eligibility rate as assessed by (the number of eligible participants / number of participants screened) x 100%

    Immediately after completion of the intervention (T2)

  • FEASIBILITY: Recruitment rate

    Recruitment rate as assessed by (the number of participants who participated in the study / number of eligible participants) x 100%

    Immediately after completion of the intervention (T2)

  • FEASIBILITY: Retention rate

    Retention rate as assessed by (the number of participants who completed the study / number of participants who enrolled in) x 100%

    Immediately after completion of the intervention (T2)

  • FEASIBILITY: Attrition rate

    Attrition rate as assessed by (the number of participants who dropped out after the randomization / number of participants who enrolled in) x 100%

    Immediately after completion of the intervention (T2)

  • FEASIBILITY: subject recruitment

    Feasibility of subject recruitment assessed by interviewing the participants' feedback regarding why they discontinued this study

    Immediately after completion of the intervention (T2)

  • FEASIBILITY: Duration for completing the subject recruitment

    Time period from the recruitment of first participants to the last patient: assessed by months

    Immediately after completion of the intervention (T2)

  • ACCEPTABILITY: Actual days of acupressure

    The number of days that the participants perform the SA interventions, where the scheduled sessions should be 7 weeks of daily acupressure

    Immediately after completion of the intervention (T2)

  • ACCEPTABILITY: duration of each acupressure session

    Duration of each time (minutes) of acupressure where the scheduled time per session should be around 36 minutes

    Immediately after completion of the intervention (T2)

  • ACCEPTABILITY: SA protocol

    Participants' feedback and satisfaction with the SA intervention assessed by a self-designed feedback form and follow-up semi-structured interviews

    Immediately after completion of the intervention (T2)

  • FEASIBILITY: Questionnaire-Item-level missing value of each questionnaire

    Item-level missing value of each questionnaire (%) assessed by the percentage of participants who do not answer any single item

    Immediately after completion of the intervention (T2)

  • FEASIBILITY: Questionnaire-Scale-level missing value of the questionnaire

    Scale-level missing value of the questionnaire (%) assessed by the percentage of participants who do not answer at least one item in the whole questionnaire

    Immediately after completion of the intervention (T2)

  • SAFETY: adverse events

    Number of adverse events occur during the intervention

    Immediately once an adverse event occurs

Secondary Outcomes (4)

  • Fatigue

    Data collection will be conducted at baseline (T1) and immediately after completion of the intervention (T2)

  • Sleep disturbance

    Data collection will be conducted at baseline (T1) and immediately after completion of the intervention (T2)

  • Depression

    Data collection will be conducted at baseline (T1) and immediately after completion of the intervention (T2)

  • Patients' quality of Life

    Data collection will be conducted at baseline (T1) and immediately after completion of the intervention (T2)

Study Arms (3)

True SA (Somatic Acupressure ) group

EXPERIMENTAL

Receiving true somatic acupressure+usual care

Other: Somatic AcupressureOther: Usual care

Sham SA group

SHAM COMPARATOR

Receiving sham somatic acupressure+usual care

Other: Sham acupressureOther: Usual care

Usual care group

OTHER

Receiving usual care only (an education booklet regarding knowledge of BC and FSD symptom cluster management advice)

Other: Usual care

Interventions

7-week self-acupressure plus usual care (an education booklet)

True SA (Somatic Acupressure ) group

Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)

Sham SA group

Usual care only (an education booklet)

Sham SA groupTrue SA (Somatic Acupressure ) groupUsual care group

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BC stage I to IIIa;
  • have experienced at least a moderate level of the FSD symptom cluster, with a score of 4 or above on a 10-point numeric rating scale, from "0 (no symptom)" to "10 (worst symptom)", for each symptom during the past one month;
  • have completed adjuvant chemotherapy for at least one month and up to three years;
  • have not scheduled chemotherapy and radiotherapy during the whole study period;
  • willing to participate in the RCT and provide written informed consent.

You may not qualify if:

  • presently taking pharmaceutical agents to treat fatigue, sleep disturbance or depression, such as antidepressant medications, psychostimulants, or hypnotics;
  • extremely weak and/or have cognitive impairment which make them unable (or difficult) to follow the study procedures and instructions;
  • having the experience of any types of SAS treatment during the past six months;
  • presently participating in any other research projects.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Affiliated Hospital Of Southwest Medical University

Luzhou, Sichuan, 646000, China

Location

Related Publications (1)

  • Wang T, Tan JB, Liu XL, Zheng SL, Zhao I, Eliseeva S, Polotan MJ, Cheng HL, Huang HQ. Implementing an evidence-based somatic acupressure intervention in breast cancer survivors with the symptom cluster of fatigue, sleep disturbance and depression: study protocol of a phase II randomised controlled trial. BMJ Open. 2022 Jan 20;12(1):e054597. doi: 10.1136/bmjopen-2021-054597.

MeSH Terms

Conditions

NeoplasmsFatigueDepressionSleep Initiation and Maintenance DisordersSyndrome

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsBehavioral SymptomsBehaviorSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental DisordersDiseasePathologic Processes

Study Officials

  • Jing-Yu (Benjamin) Tan, PhD RN

    Charles Darwin University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
This study can perform a partial blind design for participants in the true and sham intervention groups. Blind of outcome assessment will be also achieved in the true and sham intervention groups as all the questionnaires are patient-reported and the participants themselves will be the outcome assessors. Data analysis will be conducted by an independent statistician who are blinded to the group allocation.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 27, 2019

First Posted

October 8, 2019

Study Start

March 15, 2021

Primary Completion

May 17, 2022

Study Completion

July 20, 2022

Last Updated

July 21, 2022

Record last verified: 2022-07

Locations